Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D055370 | Lung Injury NIH | 0.18 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID-19 severe pneumonia.
Description: To determine the efficacy of ruxolitinib measured by overall survival
Measure: Overall survival Time: 28 days after registration into trialDescription: Assessment of the duration of ventilation support
Measure: Assessment of the duration of ventilation support Time: registration until 90 days after registration into trialDescription: Assessment of the extent of cytokine storm reduction (IL-6, CRP, ferritin)
Measure: cytokine storm Time: registration until 90 days after registration into trialDescription: To assess time on ICU
Measure: time on ICU Time: registration until 90 days after registration into trialDescription: In order to classify the severity of the AEs, number of participants with treatment-related adverse events will be assessed by the "Common Terminology Criteria for Adverse Events" (CTCAE) version 5.0
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Time: registration until 90 days after registration into trialDescription: To assess the timeframe for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)
Measure: time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG) Time: registration until 90 days after registration into trialDescription: To asses the rates of flow (liter/minute), in order to detect possible amelioration of pulmonary function after Covid-19 infection
Measure: Rates of flow Time: Discharge from hospital (end of treatment)Description: To asses gas exchange (partial pressure of oxygen and carbon dioxide), in order to detect possible amelioration of pulmonary function after Covid-19 infection
Measure: Gas exchange Time: Discharge from hospital (end of treatment)Description: To assess forced expiratory volume in 1 second (liters), in order to detect possible possible amelioration of pulmonary function after Covid-19 infection
Measure: Forced expiratory volume in 1 second (FEV1) Time: Discharge from hospital (end of treatment)Description: To assess forced vital capacity (liters), in order to detect possible possible amelioration of pulmonary function after Covid-19 infection
Measure: Forced vital capacity (FVC) Time: Discharge from hospital (end of treatment)Description: To assess Tiffeneau-Pinelli index (FEV1/FVC ratio in %), in order to detect possible possible amelioration of pulmonary function after Covid-19 infection
Measure: Tiffeneau-Pinelli index Time: Discharge from hospital (end of treatment)Description: To determine the efficacy of ruxolitinib measured by overall survival
Measure: Overall survival Time: 90 days after registration into trialAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports